Aurisco Pharmaceutical Co. Ltd. Class ASSE: 605116

"Aurisco Pharmaceutical Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing

Aug 29, 2026 · Issued by Aurisco Pharmaceutical Co. Ltd. Class A via Shanghai Stock Exchange

Announcement on Convening the 2026 Semi-annual Performance Briefing

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Aurisco Pharmaceutical Co. Ltd. Class A

"Aurisco Pharmaceutical Co., Ltd."Announcement on Obtaining Notice of Approval for Drug Supplementary Application by a Wholly-owned SubsidiaryAug 25
"Aurisco Pharmaceutical Co., Ltd."Announcement on the Wholly-owned Subsidiary Passing the U.S. FDA On-Site InspectionAug 13
"Aurisco Pharmaceutical Co., Ltd."Announcement on the Proposed Selection of the Company's Products in the 12th Batch of National Centralized Drug ProcurementAug 4
"Aurisco Pharmaceutical Co., Ltd."Announcement on 2026 Interest Payment for "Aurisco Convertible Bonds"Jul 21

All Aurisco Pharmaceutical Co. Ltd. Class A news releases